KNSA PE Ratio & Valuation, Is KNSA Overvalued

Historical Valuation

Kiniksa Pharmaceuticals International PLC (KNSA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.78 is considered Undervalued compared with the five-year average of -299.32. The fair price of Kiniksa Pharmaceuticals International PLC (KNSA) is between 2218.06 to 2225.76 according to relative valuation method. Compared to the current price of 46.74 USD , Kiniksa Pharmaceuticals International PLC By Undervalued By 97.89%.

Relative Value

Fair Zone

2218.06-2225.76

Current Price：46.74

97.89%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Kiniksa Pharmaceuticals International PLC (KNSA) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Kiniksa Pharmaceuticals International PLC (KNSA) has a current Price-to-Book (P/B) ratio of 5.92. Compared to its 3-year average P/B ratio of 3.59, the current P/B ratio is approximately 64.79% higher. Relative to its 5-year average P/B ratio of 3.67, the current P/B ratio is about 61.46% higher. Kiniksa Pharmaceuticals International PLC (KNSA) has a Forward Free Cash Flow (FCF) yield of approximately 3.20%. Compared to its 3-year average FCF yield of 2.00%, the current FCF yield is approximately 60.09% lower. Relative to its 5-year average FCF yield of -4.08%, the current FCF yield is about -178.24% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for KNSA competitors is 768.92, providing a benchmark for relative valuation. Kiniksa Pharmaceuticals International PLC Corp (KNSA.O) exhibits a P/S ratio of 3.78, which is -99.51% above the industry average. Given its robust revenue growth of 61.17%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of KNSA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of KNSA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is KNSA currently overvalued or undervalued?

Kiniksa Pharmaceuticals International PLC (KNSA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.78 is considered Undervalued compared with the five-year average of -299.32. The fair price of Kiniksa Pharmaceuticals International PLC (KNSA) is between 2218.06 to 2225.76 according to relative valuation method. Compared to the current price of 46.74 USD, Kiniksa Pharmaceuticals International PLC is Undervalued By 97.89%.

What is Kiniksa Pharmaceuticals International PLC (KNSA) fair value?

KNSA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Kiniksa Pharmaceuticals International PLC (KNSA) is between 2218.06 to 2225.76 according to relative valuation method.

How does KNSA's valuation metrics compare to the industry average?

The average P/S ratio for KNSA's competitors is 768.92, providing a benchmark for relative valuation. Kiniksa Pharmaceuticals International PLC Corp (KNSA) exhibits a P/S ratio of 3.78, which is -99.51% above the industry average. Given its robust revenue growth of 61.17%, this premium appears sustainable.

What is the current P/B ratio for Kiniksa Pharmaceuticals International PLC (KNSA) as of Mar 10 2026?

As of Mar 10 2026, Kiniksa Pharmaceuticals International PLC (KNSA) has a P/B ratio of 5.92. This indicates that the market values KNSA at 5.92 times its book value.

What is the current FCF Yield for Kiniksa Pharmaceuticals International PLC (KNSA) as of Mar 10 2026?

As of Mar 10 2026, Kiniksa Pharmaceuticals International PLC (KNSA) has a FCF Yield of 3.20%. This means that for every dollar of Kiniksa Pharmaceuticals International PLC's market capitalization, the company generates 3.20 cents in free cash flow.

What is the current Forward P/E ratio for Kiniksa Pharmaceuticals International PLC (KNSA) as of Mar 10 2026?

As of Mar 10 2026, Kiniksa Pharmaceuticals International PLC (KNSA) has a Forward P/E ratio of 27.82. This means the market is willing to pay $27.82 for every dollar of Kiniksa Pharmaceuticals International PLC's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Kiniksa Pharmaceuticals International PLC (KNSA) as of Mar 10 2026?

As of Mar 10 2026, Kiniksa Pharmaceuticals International PLC (KNSA) has a Forward P/S ratio of 3.78. This means the market is valuing KNSA at $3.78 for every dollar of expected revenue over the next 12 months.

KNSA Valuation